TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis

被引:566
作者
Chicheportiche, Y
Bourdon, PR
Xu, HD
Hsu, YM
Scott, H
Hession, C
Garcia, I
Browning, JL
机构
[1] Biogen Inc, Dept Cell Biol, Cambridge, MA 02142 USA
[2] Univ Geneva, Dept Pathol, CH-1211 Geneva 4, Switzerland
[3] Univ Geneva, Dept Genet & Microbiol, CH-1211 Geneva 4, Switzerland
[4] Biogen Inc, Dept Mol Genet, Cambridge, MA 02142 USA
[5] Biogen Inc, Dept Prot Chem, Cambridge, MA 02142 USA
关键词
D O I
10.1074/jbc.272.51.32401
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The members of the tumor necrosis factor (TNF) family play pivotal roles in the regulation of the immune system. Here we describe a new ligand in this family, designated TWEAK. The mouse and human versions of this protein are unusually conserved with 93% amino acid identity in the receptor binding domain. The protein was efficiently secreted from cells indicating that, like TNF, TWEAK may have the long range effects of a secreted cytokine. TWEAK transcripts were abundant and found in many tissues, suggesting that TWEAK and TRAIL belong to a new group of widely expressed ligands, Like many members of the TNF family, TWEAK was able to induce interleukin-8 synthesis in a number of cell lines. The human adenocarcinoma cell line, HT29, underwent apoptosis in the presence of both TWEAK and interferon-gamma. Thus, TWEAK resembles many other TNF ligands in the capacity to induce cell death; however, the fact that TWEAK-sensitive cells are relatively rare suggests that TWEAK. along with lymphotoxins alpha/beta and possibly CD30L trigger death via a weaker, nondeath domain-dependent mechanism.
引用
收藏
页码:32401 / 32410
页数:10
相关论文
共 52 条
  • [1] ABREUMARTIN MT, 1995, J IMMUNOL, V155, P4147
  • [2] CD27/CD70 INTERACTION DIRECTLY DRIVES B-CELL IGG AND IGM SYNTHESIS
    AGEMATSU, K
    KOBATA, T
    YANG, FC
    NAKAZAWA, T
    FUKUSHIMA, K
    KITAHARA, M
    MORI, T
    SUGITA, K
    MORIMOTO, C
    KOMIYAMA, A
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 1995, 25 (10) : 2825 - 2829
  • [3] Impaired negative selection of T cells in Hodgkin's disease antigen CD30-deficient mice
    Amakawa, R
    Hakem, A
    Kundig, TM
    Matsuyama, T
    Simard, JJL
    Timms, E
    Wakeham, A
    Mittruecker, HW
    Griesser, H
    Takimoto, H
    Schmits, R
    Shahinian, A
    Ohashi, PS
    Penninger, JM
    Mak, TW
    [J]. CELL, 1996, 84 (04) : 551 - 562
  • [4] TRAMP, a novel apoptosis-mediating receptor with sequence homology to tumor necrosis factor receptor 1 and Fas(Apo-1/CD95)
    Bodmer, JL
    Burns, K
    Schneider, P
    Hofmann, K
    Steiner, V
    Thome, M
    Bornand, T
    Hahne, M
    Schroter, M
    Becker, K
    Wilson, A
    French, LE
    Browning, JL
    MacDonald, HR
    Tschopp, J
    [J]. IMMUNITY, 1997, 6 (01) : 79 - 88
  • [5] CAR1, a TNFR-related protein, is a cellular receptor for cytopathic avian leukosis sarcoma viruses and mediates apoptosis
    Brojatsch, J
    Naughton, J
    Rolls, MM
    Zingler, K
    Young, JAT
    [J]. CELL, 1996, 87 (05) : 845 - 855
  • [6] BROWNING J, 1989, J IMMUNOL, V143, P1859
  • [7] Preparation and characterization of soluble recombinant heterotrimeric complexes of human lymphotoxins alpha and beta
    Browning, JL
    Miatkowski, K
    Griffiths, DA
    Bourdon, PR
    Hession, C
    Ambrose, CM
    Meier, W
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (15) : 8618 - 8626
  • [8] BROWNING JL, 1991, J IMMUNOL, V147, P1230
  • [9] Signaling through the lymphotoxin beta receptor induces the death of some adenocarcinoma tumor lines
    Browning, JL
    Miatkowski, K
    Sizing, I
    Griffiths, D
    Zafari, M
    Benjamin, CD
    Meier, W
    Mackay, F
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 183 (03) : 867 - 878
  • [10] BROWNING JL, 1995, J IMMUNOL, V154, P33